FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2283203477> ?p ?o ?g. }

• W2283203477 endingPage "25" @default.
• W2283203477 startingPage "25" @default.
• W2283203477 abstract "Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date Vladimir Trkulja Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia Abstract: Apixaban, a direct orally active anticoagulant (selective, direct factor Xa inhibitor) is approved for (primary) prevention of venous thromboembolism (VTE) in patients undergoing elective total-hip or total-knee arthroplasty, for acute treatment/prevention of recurrent events in patients with VTE, and extended prophylaxis in patients with a history of VTE. Another approved use is prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The present overview focuses on the safety of apixaban specifically in the VTE setting. Apixaban displays favorable pharmacokinetic properties: simple twice-daily dosing, low inter- and intrasubject variability, dose and time linearity, and multiple elimination pathways not critically dependent on either renal or metabolic mechanisms. An extensive nonclinical program and the overall clinical development program (all approved and tested indications) provided no signal that would indicate any particular specific safety concern related to apixaban apart from the increased risk of bleeding. With regard to the approved VTE indications, safety (and efficacy) was assessed in five large pivotal Phase III trials. In comparison to currently recommended standard treatments, apixaban shows superior efficacy, while at the same time no excess risk of bleeding in patients undergoing total-hip or total-knee arthroplasty. In treatment of VTE, apixaban shows noninferior efficacy and a reduced risk of bleeding, whereas in extended prophylaxis it reduced the risk of VTE/VTE-related deaths, with no increased risk of relevant bleedings in comparison to placebo. Documented clinical experience with apixaban in daily practice is currently sparse. However, its use is progressively increasing, and there has been no signal so far that would materially change the perception of its safety profile as defined in the premarketing trials. Keywords: apixaban, venous thromboembolism, treatment, prophylaxis, safety" @default.
• W2283203477 created "2016-06-24" @default.
• W2283203477 creator A5014187299 @default.
• W2283203477 date "2016-02-01" @default.
• W2283203477 modified "2023-09-23" @default.
• W2283203477 title "Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date" @default.
• W2283203477 cites W1507763452 @default.
• W2283203477 cites W1517835164 @default.
• W2283203477 cites W1564690174 @default.
• W2283203477 cites W1568662837 @default.
• W2283203477 cites W1572788090 @default.
• W2283203477 cites W1591205163 @default.
• W2283203477 cites W1748334772 @default.
• W2283203477 cites W1762506800 @default.
• W2283203477 cites W1870067030 @default.
• W2283203477 cites W1878559559 @default.
• W2283203477 cites W1919960999 @default.
• W2283203477 cites W1985842169 @default.
• W2283203477 cites W2001320472 @default.
• W2283203477 cites W2004044176 @default.
• W2283203477 cites W2007680892 @default.
• W2283203477 cites W2012657539 @default.
• W2283203477 cites W2014822095 @default.
• W2283203477 cites W2018856451 @default.
• W2283203477 cites W2024232617 @default.
• W2283203477 cites W2026517280 @default.
• W2283203477 cites W2027008828 @default.
• W2283203477 cites W2031424076 @default.
• W2283203477 cites W2031850616 @default.
• W2283203477 cites W2032692864 @default.
• W2283203477 cites W2038316072 @default.
• W2283203477 cites W2041979009 @default.
• W2283203477 cites W2050992159 @default.
• W2283203477 cites W2055619480 @default.
• W2283203477 cites W2060580339 @default.
• W2283203477 cites W2062346376 @default.
• W2283203477 cites W2067118403 @default.
• W2283203477 cites W2069087600 @default.
• W2283203477 cites W2071869524 @default.
• W2283203477 cites W2073493628 @default.
• W2283203477 cites W2073584640 @default.
• W2283203477 cites W2082987265 @default.
• W2283203477 cites W2086997894 @default.
• W2283203477 cites W2094800902 @default.
• W2283203477 cites W2103196751 @default.
• W2283203477 cites W2108064339 @default.
• W2283203477 cites W2110973144 @default.
• W2283203477 cites W2114189419 @default.
• W2283203477 cites W2114743668 @default.
• W2283203477 cites W2116005824 @default.
• W2283203477 cites W2117966697 @default.
• W2283203477 cites W2118615533 @default.
• W2283203477 cites W2120203545 @default.
• W2283203477 cites W2120414434 @default.
• W2283203477 cites W2120879113 @default.
• W2283203477 cites W2128563057 @default.
• W2283203477 cites W2130340163 @default.
• W2283203477 cites W2131099415 @default.
• W2283203477 cites W2133686162 @default.
• W2283203477 cites W2134683286 @default.
• W2283203477 cites W2139785591 @default.
• W2283203477 cites W2144540237 @default.
• W2283203477 cites W2162373453 @default.
• W2283203477 cites W2166402206 @default.
• W2283203477 cites W2166672545 @default.
• W2283203477 cites W2167399732 @default.
• W2283203477 cites W2989714602 @default.
• W2283203477 doi "https://doi.org/10.2147/dhps.s74410" @default.
• W2283203477 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4762581" @default.
• W2283203477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26937206" @default.
• W2283203477 hasPublicationYear "2016" @default.
• W2283203477 type Work @default.
• W2283203477 sameAs 2283203477 @default.
• W2283203477 citedByCount "0" @default.
• W2283203477 crossrefType "journal-article" @default.
• W2283203477 hasAuthorship W2283203477A5014187299 @default.
• W2283203477 hasBestOaLocation W22832034771 @default.
• W2283203477 hasConcept C126322002 @default.
• W2283203477 hasConcept C127413603 @default.
• W2283203477 hasConcept C177713679 @default.
• W2283203477 hasConcept C2776301958 @default.
• W2283203477 hasConcept C2777288759 @default.
• W2283203477 hasConcept C2778661090 @default.
• W2283203477 hasConcept C2779161974 @default.
• W2283203477 hasConcept C2780638905 @default.
• W2283203477 hasConcept C2780645631 @default.
• W2283203477 hasConcept C2780868729 @default.
• W2283203477 hasConcept C2991741193 @default.
• W2283203477 hasConcept C535046627 @default.
• W2283203477 hasConcept C71924100 @default.
• W2283203477 hasConcept C78519656 @default.
• W2283203477 hasConceptScore W2283203477C126322002 @default.
• W2283203477 hasConceptScore W2283203477C127413603 @default.
• W2283203477 hasConceptScore W2283203477C177713679 @default.
• W2283203477 hasConceptScore W2283203477C2776301958 @default.
• W2283203477 hasConceptScore W2283203477C2777288759 @default.
• W2283203477 hasConceptScore W2283203477C2778661090 @default.
• W2283203477 hasConceptScore W2283203477C2779161974 @default.

• next